Company Description

HydroGene Therapeutics has developed a non-viral DNA delivery platform to create accessible gene therapy for all liver diseases. Their technology solves the limitations of AAV-based gene therapy approaches (cost, toxicity, lack of redosing). Achieving large DNA delivery also allows for mutation agnostic correction, addressing the limitations of gene editing approaches.